Efficacy and safety of Stereotactic ablative radiotherapy (SABR) in oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) patients during abiraterone therapy.
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Abiraterone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 13 Oct 2017 New trial record
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.